The use of MuGard™, Caphosol®, and episil® in patients undergoing chemoradiotherapy for squamous cell carcinoma of the head and neck

Publisher： Cambridge University Press

E-ISSN： 1467-1131|13|1|123-124

ISSN： 1460-3969

Source： Journal of Radiotherapy in Practice, Vol.13, Iss.1, 2013-11, pp. : 123-124

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

The use of MuGard™, Caphosol® and Episil® in patients undergoing chemoradiotherapy for squamous cell carcinoma of the head and neck

By  

Journal of Radiotherapy in Practice, Vol. 13, Iss. 2, 2013-05 ,pp. : 218-225

Cambridge University Press

Access to resources Recommend Favorite

Positron Emission Tomography for Neck Evaluation Following Definitive Treatment with Chemoradiotherapy for Locoregionally Advanced Head and Neck Squamous Cell Carcinoma

By  

Reviews on Recent Clinical Trials, Vol. 7, Iss. 1, 2012-02 ,pp. : 36-41

Bentham Science Publishers

Access to resources Recommend Favorite

Multi‐institutional, randomized, double‐blind, placebo‐controlled trial to assess the efficacy of a mucoadhesive hydrogel (MuGard) in mitigating oral mucositis symptoms in patients being treated with chemoradiation therapy for cancers of the head and neck

By  

CANCER, Vol. 120, Iss. 9, 2014-05 ,pp. : 1433-1440

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cetuximab Rechallenge and Monotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck

By  

Case Reports in Oncology, Vol. 8, Iss. 3, 2015-11 ,pp. : 503-508

Karger

Access to resources Recommend Favorite

Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10‐year update and subset analysis

By  

CANCER, Vol. 121, Iss. 10, 2015-05 ,pp. : 1599-1607

John Wiley & Sons Inc

Access to resources Recommend Favorite